Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at high risk of CKD progression and cardiovascular (CV) disease. Prevalence of CKD in patients with T2D is currently around 40% and continues to grow. The increasing number of people with CKD and T2D will ultimately ...
In Tunisia, the prevalence of diabetes mellitus increased from 15.5% on 2016 to 23% by 2023. While Chronic Kidney Disease (CKD) stills the most dreaded complications of diabetes, studies on the prevalence of chronic kidney disease non-dialysis diet are scarce. The aim of this study was to ...
The AJMC® Chronic Kidney Disease compendium is a comprehensive resource for clinical news and expert insights on the condition and treatment of loss of kidney function.
Chronic kidney disease (CKD) is a major cause of complications for type 2 diabetes (T2D), which is continuing to rise and is predicted to be the fifth leading cause of death worldwide in 2040, explained Peter Rossing, MD, DMSc, he...
Early diagnosis of chronic kidney disease in patients with diabetes in France: multidisciplinary expert opinion, prevention value and practical recommendations Thierry Hannedouche, Patrick Rossignol, Patrice Darmon, Jean-Michel Halimi, Patrick Vuattoux, Albert Hagege, show all Pages 633-645 |...
In the Netherlands, more than one million patients have type 2 diabetes (T2D), and approximately 36% of these patients have chronic kidney disease (CKD). Yearly medical costs related to T2D and CKD account for approximately €1.3 billion and €805 millio
Heart failure (HF) together with type 2 diabetes (T2D) and chronic kidney disease (CKD) are major pandemics of the twenty first century. It is not known in people with new onset HF, what the distinct and combined associations are between T2D and CKD comorbidities and cause-specific hospital...
Type 2 diabetes (T2D) is a significant cause of chronic kidney disease (CKD) in Japan, leading to increased treatment needs and healthcare costs for managing both first- and second-line care in these patients. This study evaluates whether adding finerenone to the standard of care (SoC) for...
China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s Forxiga (dapagliflozin) to treat chronic kidney disease (CKD) in adult patients who are at risk of progression with and without type-2 diabetes (T2D). AstraZeneca Cambridge Biomedical Campus. Credit: AstraZeneca....
Chronic kidney disease (CKD) has become a concerning public health issue, affecting people regardless of their sex, age, or socioeconomic status. We aimed to analyze the burden of female CKD in Mexico between 1990 and 2021, expressed in terms of years lived with disability (YLDs), mortality,...